Copenhagen, Denmark; April 30, 2014 – Genmab A/S (OMX: GEN) announced today that net sales of Arzerra (ofatumumab) during the first quarter of 2014 were GBP 15.6 million (approximately DKK 140 million). This figure consists of net sales in the US of GBP 10.1 million and in the rest of the world of GBP 5.5 million. Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK 28 million.
Help employers find you! Check out all the jobs and post your resume.
